 | • レポートコード：GIR-107A15036 • 出版社/出版日：GlobalInfoResearch / 2021年7月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医薬品 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、神経内分泌がんのグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。神経内分泌がんの種類別市場規模（化学療法、ソマトスタチン類似体、標的療法）、用途別市場規模（病院、クリニック、腫瘍センター、外来手術センター）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・神経内分泌がんの市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Pfizer、Novartis、Chiasma、Ipsen、Abbvie、Valeant、Jubilant、Teva、F.Hoffmann-La Roche、Advanced Accelerator、Mateon、Lexicon ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：化学療法、ソマトスタチン類似体、標的療法 ・用途別分析2016年-2026年：病院、クリニック、腫瘍センター、外来手術センター ・神経内分泌がんの北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・神経内分泌がんのヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・神経内分泌がんのアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・神経内分泌がんの南米市場規模2016年-2026年：ブラジル、アルゼンチン ・神経内分泌がんの中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Neuroendocrine Carcinoma market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Neuroendocrine Carcinoma size is estimated to be USD xx million in 2026 from USD xx million in 2020, with a change XX% between 2020 and 2021. The global Neuroendocrine Carcinoma market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Neuroendocrine Carcinoma market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy
Somatostatin Analogs
Targeted Therapy
Market segment by Application, can be divided into
Hospital
Clinics
Oncology Centres
Ambulatory Surgery Centres
Market segment by players, this report covers
Pfizer
Novartis
Chiasma
Ipsen
Abbvie
Valeant
Jubilant
Teva
F.Hoffmann-La Roche
Advanced Accelerator
Mateon
Lexicon
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Neuroendocrine Carcinoma product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Neuroendocrine Carcinoma, with revenue, gross margin and global market share of Neuroendocrine Carcinoma from 2019 to 2021.
Chapter 3, the Neuroendocrine Carcinoma competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by type and application, with revenue and growth rate by type, application, from 2016 to 2026.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2016 to 2021.and Neuroendocrine Carcinoma market forecast, by regions, type and application, with revenue, from 2021 to 2026.
Chapter 11 and 12, to describe Neuroendocrine Carcinoma research findings and conclusion, appendix and data source.
1 Market Overview
1.1 Product Overview and Scope of Neuroendocrine Carcinoma
1.2 Classification of Neuroendocrine Carcinoma by Type
1.2.1 Overview: Global Neuroendocrine Carcinoma Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Neuroendocrine Carcinoma Revenue Market Share by Type in 2020
1.2.3 Chemotherapy
1.2.4 Somatostatin Analogs
1.2.5 Targeted Therapy
1.3 Global Neuroendocrine Carcinoma Market by Application
1.3.1 Overview: Global Neuroendocrine Carcinoma Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Oncology Centres
1.3.5 Ambulatory Surgery Centres
1.4 Global Neuroendocrine Carcinoma Market Size & Forecast
1.5 Global Neuroendocrine Carcinoma Market Size and Forecast by Region
1.5.1 Global Neuroendocrine Carcinoma Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Neuroendocrine Carcinoma Market Size by Region, (2016-2021)
1.5.3 North America Neuroendocrine Carcinoma Market Size and Prospect (2016-2026)
1.5.4 Europe Neuroendocrine Carcinoma Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Neuroendocrine Carcinoma Market Size and Prospect (2016-2026)
1.5.6 South America Neuroendocrine Carcinoma Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Neuroendocrine Carcinoma Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Neuroendocrine Carcinoma Market Drivers
1.6.2 Neuroendocrine Carcinoma Market Restraints
1.6.3 Neuroendocrine Carcinoma Trends Analysis
2 Company Profiles
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer Neuroendocrine Carcinoma Product and Solutions
2.1.4 Pfizer Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Pfizer Recent Developments and Future Plans
2.2 Novartis
2.2.1 Novartis Details
2.2.2 Novartis Major Business
2.2.3 Novartis Neuroendocrine Carcinoma Product and Solutions
2.2.4 Novartis Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Novartis Recent Developments and Future Plans
2.3 Chiasma
2.3.1 Chiasma Details
2.3.2 Chiasma Major Business
2.3.3 Chiasma Neuroendocrine Carcinoma Product and Solutions
2.3.4 Chiasma Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Chiasma Recent Developments and Future Plans
2.4 Ipsen
2.4.1 Ipsen Details
2.4.2 Ipsen Major Business
2.4.3 Ipsen Neuroendocrine Carcinoma Product and Solutions
2.4.4 Ipsen Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Ipsen Recent Developments and Future Plans
2.5 Abbvie
2.5.1 Abbvie Details
2.5.2 Abbvie Major Business
2.5.3 Abbvie Neuroendocrine Carcinoma Product and Solutions
2.5.4 Abbvie Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Abbvie Recent Developments and Future Plans
2.6 Valeant
2.6.1 Valeant Details
2.6.2 Valeant Major Business
2.6.3 Valeant Neuroendocrine Carcinoma Product and Solutions
2.6.4 Valeant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Valeant Recent Developments and Future Plans
2.7 Jubilant
2.7.1 Jubilant Details
2.7.2 Jubilant Major Business
2.7.3 Jubilant Neuroendocrine Carcinoma Product and Solutions
2.7.4 Jubilant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Jubilant Recent Developments and Future Plans
2.8 Teva
2.8.1 Teva Details
2.8.2 Teva Major Business
2.8.3 Teva Neuroendocrine Carcinoma Product and Solutions
2.8.4 Teva Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Teva Recent Developments and Future Plans
2.9 F.Hoffmann-La Roche
2.9.1 F.Hoffmann-La Roche Details
2.9.2 F.Hoffmann-La Roche Major Business
2.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product and Solutions
2.9.4 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 F.Hoffmann-La Roche Recent Developments and Future Plans
2.10 Advanced Accelerator
2.10.1 Advanced Accelerator Details
2.10.2 Advanced Accelerator Major Business
2.10.3 Advanced Accelerator Neuroendocrine Carcinoma Product and Solutions
2.10.4 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.10.5 Advanced Accelerator Recent Developments and Future Plans
2.11 Mateon
2.11.1 Mateon Details
2.11.2 Mateon Major Business
2.11.3 Mateon Neuroendocrine Carcinoma Product and Solutions
2.11.4 Mateon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.11.5 Mateon Recent Developments and Future Plans
2.12 Lexicon
2.12.1 Lexicon Details
2.12.2 Lexicon Major Business
2.12.3 Lexicon Neuroendocrine Carcinoma Product and Solutions
2.12.4 Lexicon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2019-2021)
2.12.5 Lexicon Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Neuroendocrine Carcinoma Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 3 Neuroendocrine Carcinoma Players Market Share
3.2.2 Top 10 Neuroendocrine Carcinoma Players Market Share
3.2.3 Market Competition Trend
3.3 Neuroendocrine Carcinoma Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Neuroendocrine Carcinoma Revenue and Market Share by Type (2016-2021)
4.2 Global Neuroendocrine Carcinoma Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Neuroendocrine Carcinoma Revenue Market Share by Application (2016-2021)
5.2 Neuroendocrine Carcinoma Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Neuroendocrine Carcinoma Revenue by Type (2016-2026)
6.2 North America Neuroendocrine Carcinoma Revenue by Application (2016-2026)
6.3 North America Neuroendocrine Carcinoma Market Size by Country
6.3.1 North America Neuroendocrine Carcinoma Revenue by Country (2016-2026)
6.3.2 United States Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
6.3.3 Canada Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
6.3.4 Mexico Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Neuroendocrine Carcinoma Revenue by Type (2016-2026)
7.2 Europe Neuroendocrine Carcinoma Revenue by Application (2016-2026)
7.3 Europe Neuroendocrine Carcinoma Market Size by Country
7.3.1 Europe Neuroendocrine Carcinoma Revenue by Country (2016-2026)
7.3.2 Germany Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
7.3.3 France Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
7.3.5 Russia Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
7.3.6 Italy Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Neuroendocrine Carcinoma Revenue by Type (2016-2026)
8.2 Asia-Pacific Neuroendocrine Carcinoma Revenue by Application (2016-2026)
8.3 Asia-Pacific Neuroendocrine Carcinoma Market Size by Region
8.3.1 Asia-Pacific Neuroendocrine Carcinoma Revenue by Region (2016-2026)
8.3.2 China Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8.3.3 Japan Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8.3.4 South Korea Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8.3.5 India Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
8.3.7 Australia Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Neuroendocrine Carcinoma Revenue by Type (2016-2026)
9.2 South America Neuroendocrine Carcinoma Revenue by Application (2016-2026)
9.3 South America Neuroendocrine Carcinoma Market Size by Country
9.3.1 South America Neuroendocrine Carcinoma Revenue by Country (2016-2026)
9.3.2 Brazil Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
9.3.3 Argentina Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Neuroendocrine Carcinoma Revenue by Type (2016-2026)
10.2 Middle East & Africa Neuroendocrine Carcinoma Revenue by Application (2016-2026)
10.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Country
10.3.1 Middle East & Africa Neuroendocrine Carcinoma Revenue by Country (2016-2026)
10.3.2 Turkey Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
10.3.4 UAE Neuroendocrine Carcinoma Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Neuroendocrine Carcinoma Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Neuroendocrine Carcinoma Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Neuroendocrine Carcinoma Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Neuroendocrine Carcinoma Revenue (USD Million) by Region (2016-2021)
Table 5. Global Neuroendocrine Carcinoma Revenue Market Share by Region (2021-2026)
Table 6. Pfizer Corporate Information, Head Office, and Major Competitors
Table 7. Pfizer Major Business
Table 8. Pfizer Neuroendocrine Carcinoma Product and Solutions
Table 9. Pfizer Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Novartis Corporate Information, Head Office, and Major Competitors
Table 11. Novartis Major Business
Table 12. Novartis Neuroendocrine Carcinoma Product and Solutions
Table 13. Novartis Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Chiasma Corporate Information, Head Office, and Major Competitors
Table 15. Chiasma Major Business
Table 16. Chiasma Neuroendocrine Carcinoma Product and Solutions
Table 17. Chiasma Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Ipsen Corporate Information, Head Office, and Major Competitors
Table 19. Ipsen Major Business
Table 20. Ipsen Neuroendocrine Carcinoma Product and Solutions
Table 21. Ipsen Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Abbvie Corporate Information, Head Office, and Major Competitors
Table 23. Abbvie Major Business
Table 24. Abbvie Neuroendocrine Carcinoma Product and Solutions
Table 25. Abbvie Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Valeant Corporate Information, Head Office, and Major Competitors
Table 27. Valeant Major Business
Table 28. Valeant Neuroendocrine Carcinoma Product and Solutions
Table 29. Valeant Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Jubilant Corporate Information, Head Office, and Major Competitors
Table 31. Jubilant Major Business
Table 32. Jubilant Neuroendocrine Carcinoma Product and Solutions
Table 33. Jubilant Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Teva Corporate Information, Head Office, and Major Competitors
Table 35. Teva Major Business
Table 36. Teva Neuroendocrine Carcinoma Product and Solutions
Table 37. Teva Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. F.Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 39. F.Hoffmann-La Roche Major Business
Table 40. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product and Solutions
Table 41. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Advanced Accelerator Corporate Information, Head Office, and Major Competitors
Table 43. Advanced Accelerator Major Business
Table 44. Advanced Accelerator Neuroendocrine Carcinoma Product and Solutions
Table 45. Advanced Accelerator Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 46. Mateon Corporate Information, Head Office, and Major Competitors
Table 47. Mateon Major Business
Table 48. Mateon Neuroendocrine Carcinoma Product and Solutions
Table 49. Mateon Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 50. Lexicon Corporate Information, Head Office, and Major Competitors
Table 51. Lexicon Major Business
Table 52. Lexicon Neuroendocrine Carcinoma Product and Solutions
Table 53. Lexicon Neuroendocrine Carcinoma Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 54. Global Neuroendocrine Carcinoma Revenue (USD Million) by Players (2019-2021)
Table 55. Global Neuroendocrine Carcinoma Revenue Share by Players (2019-2021)
Table 56. Breakdown of Neuroendocrine Carcinoma by Company Type (Tier 1, Tier 2 and Tier 3)
Table 57. Neuroendocrine Carcinoma Players Head Office, Products and Services Provided
Table 58. Neuroendocrine Carcinoma Mergers & Acquisitions in the Past Five Years
Table 59. Neuroendocrine Carcinoma New Entrants and Expansion Plans
Table 60. Global Neuroendocrine Carcinoma Revenue (USD Million) by Type (2016-2021)
Table 61. Global Neuroendocrine Carcinoma Revenue Share by Type (2016-2021)
Table 62. Global Neuroendocrine Carcinoma Revenue Forecast by Type (2021-2026)
Table 63. Global Neuroendocrine Carcinoma Revenue by Application (2016-2021)
Table 64. Global Neuroendocrine Carcinoma Revenue Forecast by Application (2021-2026)
Table 65. North America Neuroendocrine Carcinoma Revenue by Type (2016-2021) & (USD Million)
Table 66. North America Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (USD Million)
Table 67. North America Neuroendocrine Carcinoma Revenue by Application (2016-2021) & (USD Million)
Table 68. North America Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (USD Million)
Table 69. North America Neuroendocrine Carcinoma Revenue by Country (2016-2021) & (USD Million)
Table 70. North America Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (USD Million)
Table 71. Europe Neuroendocrine Carcinoma Revenue by Type (2016-2021) & (USD Million)
Table 72. Europe Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (USD Million)
Table 73. Europe Neuroendocrine Carcinoma Revenue by Application (2016-2021) & (USD Million)
Table 74. Europe Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (USD Million)
Table 75. Europe Neuroendocrine Carcinoma Revenue by Country (2016-2021) & (USD Million)
Table 76. Europe Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (USD Million)
Table 77. Asia-Pacific Neuroendocrine Carcinoma Revenue by Type (2016-2021) & (USD Million)
Table 78. Asia-Pacific Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (USD Million)
Table 79. Asia-Pacific Neuroendocrine Carcinoma Revenue by Application (2016-2021) & (USD Million)
Table 80. Asia-Pacific Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (USD Million)
Table 81. Asia-Pacific Neuroendocrine Carcinoma Revenue by Region (2016-2021) & (USD Million)
Table 82. Asia-Pacific Neuroendocrine Carcinoma Revenue by Region (2021-2026) & (USD Million)
Table 83. South America Neuroendocrine Carcinoma Revenue by Type (2016-2021) & (USD Million)
Table 84. South America Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (USD Million)
Table 85. South America Neuroendocrine Carcinoma Revenue by Application (2016-2021) & (USD Million)
Table 86. South America Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (USD Million)
Table 87. South America Neuroendocrine Carcinoma Revenue by Country (2016-2021) & (USD Million)
Table 88. South America Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (USD Million)
Table 89. Middle East & Africa Neuroendocrine Carcinoma Revenue by Type (2016-2021) & (USD Million)
Table 90. Middle East & Africa Neuroendocrine Carcinoma Revenue by Type (2021-2026) & (USD Million)
Table 91. Middle East & Africa Neuroendocrine Carcinoma Revenue by Application (2016-2021) & (USD Million)
Table 92. Middle East & Africa Neuroendocrine Carcinoma Revenue by Application (2021-2026) & (USD Million)
Table 93. Middle East & Africa Neuroendocrine Carcinoma Revenue by Country (2016-2021) & (USD Million)
Table 94. Middle East & Africa Neuroendocrine Carcinoma Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Neuroendocrine Carcinoma Picture
Figure 2. Global Neuroendocrine Carcinoma Revenue Market Share by Type in 2020
Figure 3. Chemotherapy
Figure 4. Somatostatin Analogs
Figure 5. Targeted Therapy
Figure 6. Neuroendocrine Carcinoma Revenue Market Share by Application in 2020
Figure 7. Hospital Picture
Figure 8. Clinics Picture
Figure 9. Oncology Centres Picture
Figure 10. Ambulatory Surgery Centres Picture
Figure 11. Global Neuroendocrine Carcinoma Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 12. Global Neuroendocrine Carcinoma Revenue and Forecast (2016-2026) & (USD Million)
Figure 13. Global Neuroendocrine Carcinoma Revenue Market Share by Region (2016-2026)
Figure 14. Global Neuroendocrine Carcinoma Revenue Market Share by Region in 2020
Figure 15. North America Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Europe Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 17. Asia-Pacific Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 18. South America Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 19. Middle East and Africa Neuroendocrine Carcinoma Revenue (USD Million) and Growth Rate (2016-2026)
Figure 20. Neuroendocrine Carcinoma Market Drivers
Figure 21. Neuroendocrine Carcinoma Market Restraints
Figure 22. Neuroendocrine Carcinoma Market Trends
Figure 23. Pfizer Recent Developments and Future Plans
Figure 24. Novartis Recent Developments and Future Plans
Figure 25. Chiasma Recent Developments and Future Plans
Figure 26. Ipsen Recent Developments and Future Plans
Figure 27. Abbvie Recent Developments and Future Plans
Figure 28. Valeant Recent Developments and Future Plans
Figure 29. Jubilant Recent Developments and Future Plans
Figure 30. Teva Recent Developments and Future Plans
Figure 31. F.Hoffmann-La Roche Recent Developments and Future Plans
Figure 32. Advanced Accelerator Recent Developments and Future Plans
Figure 33. Mateon Recent Developments and Future Plans
Figure 34. Lexicon Recent Developments and Future Plans
Figure 35. Global Neuroendocrine Carcinoma Revenue Share by Players in 2020
Figure 36. Neuroendocrine Carcinoma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 37. Global Top 3 Players Neuroendocrine Carcinoma Revenue Market Share in 2020
Figure 38. Global Top 10 Players Neuroendocrine Carcinoma Revenue Market Share in 2020
Figure 39. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 40. Global Neuroendocrine Carcinoma Revenue Share by Type in 2020
Figure 41. Global Neuroendocrine Carcinoma Market Share Forecast by Type (2021-2026)
Figure 42. Global Neuroendocrine Carcinoma Revenue Share by Application in 2020
Figure 43. Global Neuroendocrine Carcinoma Market Share Forecast by Application (2021-2026)
Figure 44. North America Neuroendocrine Carcinoma Sales Market Share by Type (2016-2026)
Figure 45. North America Neuroendocrine Carcinoma Sales Market Share by Application (2016-2026)
Figure 46. North America Neuroendocrine Carcinoma Revenue Market Share by Country (2016-2026)
Figure 47. United States Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. Canada Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. Mexico Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Europe Neuroendocrine Carcinoma Sales Market Share by Type (2016-2026)
Figure 51. Europe Neuroendocrine Carcinoma Sales Market Share by Application (2016-2026)
Figure 52. Europe Neuroendocrine Carcinoma Revenue Market Share by Country (2016-2026)
Figure 53. Germany Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 54. France Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 55. United Kingdom Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Russia Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. Italy Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. Asia-Pacific Neuroendocrine Carcinoma Sales Market Share by Type (2016-2026)
Figure 59. Asia-Pacific Neuroendocrine Carcinoma Sales Market Share by Application (2016-2026)
Figure 60. Asia-Pacific Neuroendocrine Carcinoma Revenue Market Share by Region (2016-2026)
Figure 61. China Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 62. Japan Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 63. South Korea Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 64. India Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Southeast Asia Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Australia Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 67. South America Neuroendocrine Carcinoma Sales Market Share by Type (2016-2026)
Figure 68. South America Neuroendocrine Carcinoma Sales Market Share by Application (2016-2026)
Figure 69. South America Neuroendocrine Carcinoma Revenue Market Share by Country (2016-2026)
Figure 70. Brazil Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. Argentina Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by Type (2016-2026)
Figure 73. Middle East and Africa Neuroendocrine Carcinoma Sales Market Share by Application (2016-2026)
Figure 74. Middle East and Africa Neuroendocrine Carcinoma Revenue Market Share by Country (2016-2026)
Figure 75. Turkey Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 76. Saudi Arabia Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 77. UAE Neuroendocrine Carcinoma Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 78. Methodology
Figure 79. Research Process and Data Source
神経内分泌がん市場：世界及び中国市場分析・予測（～2024年） Neuroendocrine Carcinoma Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Neuroendocrine Carcinoma industry with a focus on the Chinese market. The report provides key statistics on the market status of the Neuroendocrine Carci…- 神経内分泌腫瘍治療の世界市場 2019年版：種類別（エベロリムス、スニチニブ、Lu-Dotatate、ランレオタイド、オクトレオチド）、用途別（病院、診療所、その他） Scope of the Report: The global Neuroendocrine Tumor Treatment market is valued at xx million USD in 2018 and is expected to reach xx million USD by the end of 2024, growing at a CAGR of xx% between 2019 and 2024. The Asia-Pacific will occupy for more market share in following years, especially in C…
- 神経内分泌腫瘍治療薬市場：世界及び中国市場分析・予測（～2024年） Neuroendocrine Tumor Drug Market Insights 2019, Global and Chinese Scenario is a professional and in-depth study on the current state of the global Neuroendocrine Tumor Drug industry with a focus on the Chinese market. The report provides key statistics on the market status of the Neuroendocrine Tum…
- 世界の胸腺がん治療市場 2021：企業別、地域別、種類・用途別 The Thymic Carcinoma Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regu…
- 世界の肝細胞癌治療薬市場 2021：企業別、地域別、種類・用途別 The Hepatocellular Carcinoma Drug market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade r…